Recently, Viva Biotech's portfolio companies have new updates: TechnoDerma, VivaVision, Arthrosi, Apeiron Therapeutics and AceLink made solid progress in R&D; Full Circles published breakthrough ...

The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities ...

ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.

Major positive events in 2024 include India’s first solar-powered remote village, the discovery of plastic-decomposing worms, ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Jefferies analyst Maury Raycroft maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...

At the same time, the company will push ahead with other pipeline candidates, including its Fabry disease program, for which it is hoping to submit a BLA in the second half of 2025. Fabry disease is a ...

Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following ...

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending Sangamo’s shares crashing ...

4D-310 is under development for the treatment of Fabry disease. The drug candidate is administered through intravenous route. The drug candidate is based on vector evolution platform technology that ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

INR:2267. gali disawar mein kya i The reshuffle of senior management continues as the president of Novartis USA is replaced! Review period for new drug fo ...